Chemotherapy is the basic treatments for lung cancer, and nausea and vomiting is one of the most common adverse event of chemotherapy, which decrease the life quality. As a result, how to prevent chemotherapy induced nausea and vomiting(CINV) is an important subject faced by oncologists. The granisetron transdermal delivery system (GTDS) has been developed to deliver granisetron continuously over 7 days to prevent CINV. Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant. But there is no similar studies at home and abroad.
Our study prospectively assessed the non-inferiority of the GTDS plus dexamethasone to the GTDS plus dexamethasone and aprepitant in patients receiving multiday HEC. The primary endpoint was the proportion of patients with complete control of CINV from chemotherapy initiation until 24 h after final administration. The study has already enrolled 40 patients, 21 patients with two regimens, and 19 patients with three regimens before receiving multiday HEC.
Between January 2019 and June 2020, 40 patients was recruited in the analysis. The GTDS plus dexamethasone group displayed non-inferiority to The GTDS plus dexamethasone and aprepitant group, complete control was achieved by 63.6% of patients in the two regimens group, and 65.4% in the three regimens group (P>0.05). Both treatments were well tolerated, the most common adverse events are manageable.
Current guidelines for the management of multiday HEC recommend three regimens therapy. Our study indicate that the two regimens therapy provides effective, well-tolerated control of multiday HEC. It offers a alternative route for delivering two regimens for up to 7 days that is as effective as three regimens.
The authors.
Has not received any funding.
All authors have declared no conflicts of interest.